Headlines about OraSure Technologies (NASDAQ:OSUR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 46.658035741622 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have effected Accern’s rankings:

OraSure Technologies (OSUR) opened at 20.73 on Friday. The stock has a market capitalization of $1.23 billion, a P/E ratio of 38.32 and a beta of 1.57. OraSure Technologies has a one year low of $6.84 and a one year high of $21.59. The stock has a 50 day moving average price of $18.48 and a 200-day moving average price of $14.08.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm earned $0.07 earnings per share. Analysts anticipate that OraSure Technologies will post $0.48 earnings per share for the current year.

A number of research analysts have recently issued reports on OSUR shares. Jefferies Group LLC lifted their price target on OraSure Technologies from $12.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, May 4th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Saturday, May 6th. Canaccord Genuity lifted their price target on OraSure Technologies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, June 28th. Stephens reiterated an “overweight” rating and issued a $19.00 price target (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Finally, BidaskClub downgraded OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $15.46.

ILLEGAL ACTIVITY WARNING: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/13/orasure-technologies-osur-earns-daily-media-sentiment-score-of-0-21.html.

In related news, CEO Douglas A. Michels sold 290,495 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total value of $4,865,791.25. Following the transaction, the chief executive officer now owns 894,012 shares of the company’s stock, valued at $14,974,701. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Anthony Zezzo II sold 72,916 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.26, for a total value of $1,550,194.16. Following the completion of the transaction, the executive vice president now directly owns 218,326 shares in the company, valued at approximately $4,641,610.76. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,036,670 shares of company stock worth $19,807,152. Insiders own 7.80% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.